Hepcidin as well as TNF-α are significant predictors of arterial stiffness in patients on maintenance hemodialysis.
BACKGROUND
Dysregulated iron metabolism has been suspected to be linked to anemia of chronic disease and to cardiovascular disease (CVD). For the purpose of clarifying the factors affecting arterial stiffness, we evaluated the relationship between iron metabolism, brachial-ankle (ba)-pulse wave velocity (PWV) and several risk factors for CVD in maintenance hemodialysis (MHD) patients.


METHODS
A total of 168 MHD patients were recruited, and the levels of iron parameters, hepcidin, CVD risk factors and ba-PWV were evaluated. The level of serum hepcidin-25 was specifically measured by liquid chromatography-tandem mass spectrometry.


RESULTS
Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and hepcidin were higher in MHD patients, which was consistent with results from our previous study. ba-PWV significantly correlated with age (P < 0.01, R = 0.34), total cholesterol (T-CHO; P = 0.02, R = 0.21), TNF-α (P < 0.01, R = 0.24) and hepcidin (P < 0.01, R = 0.25) but not with other iron parameters and CVD risk factors. According to multiple regression analysis, age (β = 0.30), T-CHO (β = 0.24) TNF-α (β = 0.19) and hepcidin (β = 0.23) were selected as the significant predictors of ba-PWV in MHD patients.


CONCLUSIONS
Serum levels of both hepcidin and TNF-α are independently associated with arterial stiffness in MHD patients, suggesting that microinflammation and iron metabolism might affect the integrity of arterial walls.
Department of Internal Medicine, Division of Kidney and Dialysis, Hyogo College of Medicine, Nishinomiya, Japan. kuragano@hyo-med.ac.jp
Takahiro
T
Kuragano
Katsukiyo
K
Itoh
Yasushi
Y
Shimonaka
Aritoshi
A
Kida
Minoru
M
Furuta
Rie
R
Kitamura
Mana
M
Yahiro
Masayohi
M
Nanami
Yoshinaga
Y
Otaki
Yukiko
Y
Hasuike
Hiroshi
H
Nonoguchi
Takeshi
T
Nakanishi
D023181:Antimicrobial Cationic Peptides / Q000097:blood*; D015415:Biomarkers / Q000378:metabolism*; D001783:Blood Flow Velocity; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D064451:Hepcidins; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D007676:Kidney Failure, Chronic / Q000628:therapy; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011673:Pulsatile Flow; D006435:Renal Dialysis / Q000009:adverse effects*; D012307:Risk Factors; D015996:Survival Rate; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*; D059289:Vascular Stiffness
D023181:Antimicrobial Cationic Peptides; D015415:Biomarkers; C578702:HAMP protein, human; D064451:Hepcidins; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha